Protective Effect of Combined Caffeic Acid Phenethyl Ester and Bevacizumab Against Hydrogen Peroxide-Induced Oxidative Stress in Human RPE Cells

Curr Eye Res. 2017 Dec;42(12):1659-1666. doi: 10.1080/02713683.2017.1368085. Epub 2017 Sep 22.

Abstract

Purpose: This study aimed to evaluate the protective effects of caffeic acid phenethyl ester (CAPE) and combined CAPE-bevacizumab against oxidative stress induced by hydrogen peroxide (H2O2) in human retinal pigment epithelium.

Methods: ARPE-19 cells were pretreated with 5, 10, and 30 μM CAPE alone and in combination with bevacizumab for 3 h, then exposed to H2O2 for 16 h. Cell viability was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Vascular endothelial growth factor (VEGF) protein levels in the medium were measured using a human VEGF ELISA kit. Total antioxidant status (TAS) and total oxidant status (TOS) were measured in ARPE-19 cells using the test kit from Rel Assay. Expression levels of VEGF, Bax, Bcl-2, cytochrome c, apoptotic protease activating factor-1 (apaf-1), and caspase-3 were determined using reverse transcription polymerase chain reaction.

Results: Pretreatment of ARPE-19 cells with 30 μM CAPE and combined CAPE-bevacizumab reduced H2O2 mediated cell death. H2O2-induced oxidative stress increased TOS and VEGF production, which was significantly inhibited by CAPE and the CAPE-bevacizumab combination. VEGF, Bax, cytochrome c, apaf-1, and caspase-3 gene expressions were significantly decreased in cells pretreated with 5, 10, and 30 μM CAPE and combined CAPE-bevacizumab compared to the H2O2 group. In addition, Bcl-2 expression was significantly increased in both the CAPE and CAPE-bevacizumab combination groups compared to the H2O2 group.

Conclusions: CAPE has a protective effect on ARPE-19 cells against oxidative stress, and VEGF protein level and expression can be decreased by incubation with different concentrations of CAPE. These results demonstrate that CAPE suppresses the mitochondria-mediated apoptosis in ARPE-19 cells under oxidative stress. In addition, the use of CAPE in combination with bevacizumab has an additive effect.

Keywords: Age related macular degeneration; CAPE; bevacizumab; caffeic acid phenethyl ester; oxidative stress; retinal pigment epithelium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Apoptotic Protease-Activating Factor 1 / genetics
  • Bevacizumab / pharmacology*
  • Caffeic Acids / pharmacology*
  • Caspase 3 / genetics
  • Cell Line
  • Cell Survival / drug effects
  • Cytochromes c / genetics
  • Drug Therapy, Combination
  • Enzyme-Linked Immunosorbent Assay
  • Gene Expression Regulation / physiology
  • Humans
  • Hydrogen Peroxide / toxicity*
  • Oxidants / toxicity*
  • Oxidative Stress / drug effects*
  • Phenylethyl Alcohol / analogs & derivatives*
  • Phenylethyl Alcohol / pharmacology
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Reactive Oxygen Species / metabolism
  • Real-Time Polymerase Chain Reaction
  • Retinal Pigment Epithelium / drug effects*
  • Retinal Pigment Epithelium / metabolism
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism
  • bcl-2-Associated X Protein / genetics

Substances

  • APAF1 protein, human
  • Angiogenesis Inhibitors
  • Apoptotic Protease-Activating Factor 1
  • BCL2 protein, human
  • Caffeic Acids
  • Oxidants
  • Proto-Oncogene Proteins c-bcl-2
  • Reactive Oxygen Species
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • bcl-2-Associated X Protein
  • Bevacizumab
  • Cytochromes c
  • Hydrogen Peroxide
  • Caspase 3
  • caffeic acid phenethyl ester
  • Phenylethyl Alcohol